506943 logo

J. B. Chemicals & Pharmaceuticals Limited Stock Price

BSE:506943 Community·₹352.6b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 7 Fair Values set on narratives written by author

506943 Share Price Performance

₹2,196.30
495.30 (29.12%)
₹2,242.13
Fair Value
₹2,196.30
495.30 (29.12%)
2.0% undervalued intrinsic discount
₹2,242.13
Fair Value
Price ₹2,196.30
AnalystConsensusTarget ₹2,242.13

506943 Community Narratives

·
Fair Value ₹2.24k 2.0% undervalued intrinsic discount

Chronic Therapeutic Demand And CDMO Launches Will Extend Global Reach

0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
₹2.24k
2.0% undervalued intrinsic discount
Revenue
11.44% p.a.
Profit Margin
21.71%
Future PE
40.31x
Price in 2029
₹3.18k

Trending Discussion

Updated Narratives

506943 logo

506943: Board Transitions And Dividend Decision Will Shape A Steady Long Term Outlook

Fair Value: ₹2.24k 2.0% undervalued intrinsic discount
4 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet with solid track record and pays a dividend.

1 Risk
2 Rewards

J. B. Chemicals & Pharmaceuticals Limited Key Details

₹41.9b

Revenue

₹13.8b

Cost of Revenue

₹28.1b

Gross Profit

₹20.6b

Other Expenses

₹7.5b

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
46.95
67.05%
17.98%
1.1%
View Full Analysis

About 506943

Founded
1976
Employees
5304
CEO
n/a
WebsiteView website
www.jbpharma.com

J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company’s API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; and nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, capsules, liquids, gels, lozenges, creams, injectables, powder, cold rubs, eye drops, and troches; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, the company offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners; and contract manufacturing services. It provides its products to gastroenterology, anti-infectives, wound care, neonatology and pediatrics, genecology, dental, vitamins and minerals, hypertension, diabetes, nephrology, respiratory, pain-analgesic, dermatology, antivirals, lozenges, and contrast media and radio diagnostic therapeutic areas. J. B. Chemicals & Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Mumbai, India.

Recent 506943 News & Updates

Narrative Update May 11

506943: Board Transitions And Dividend Decision Will Shape A Steady Long Term Outlook

Analysts have nudged their price target on J. B.

Recent updates

No updates